Clinical Trials Sponsored by Ocugen

Total 79 results

Ocugen

Recruiting

Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease (GARDian)

Stargardt Disease

United States
Ocugen

No longer available

Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older

COVID-19

United States
Ocugen

Not yet recruiting

Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) (DME)

Diabetic Macular Edema | Center Involved Diabetic Macular Edema
Ocugen

Recruiting

Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults

COVID-19

United States
Ocugen

Recruiting

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis (OCU400)

Retinitis Pigmentosa | Leber Congenital Amaurosis

United States
Ocugen

Terminated

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease (oGVHD)

Graft vs Host Disease | Ocular Surface Disease | Graft Versus Host Disease | Ocular Graft vs Host Disease | Ophthalmic Solutions | oGVHD | Brimonidine Tartrate | Lubricant Eye Drops

United States
Ocugen

Recruiting

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy (ArMaDa)

Geographic Atrophy

United States
Ocugen

Completed

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

Dry Eye

United States
Ocugen

Completed

Dry Eye Disease Study With Brimonidine

Dry Eye

United States
Icagen

Completed

Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects

Atopic Asthma

United Kingdom
Icagen

Completed

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

Sickle Cell Disease | Sickle Cell Anemia

United States
Okogen

Active, not recruiting

OKG-0301 for the Treatment of Acute Adenoviral Conjunctivitis (RUBY)

Adenoviral Conjunctivitis

Australia
Icagen

Completed

Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma

Exercise Induced Asthma

United States
Cugene Inc.

Recruiting

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | Autoimmune | SLE (Systemic Lupus)

United States
FluGen Inc

Completed

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Influenza A

United States
Tocagen Inc.

Withdrawn

A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care (Toca7)

Newly Diagnosed High Grade Glioma (HGG)
Tocagen Inc.

Terminated

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Melanoma | Sarcoma | Lymphoma | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | IDH1 Mutated Solid Tumors | IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

United States
Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Oxagen Ltd

Completed

Proof of Concept Study of OC000459 in Eosinophilic Esophagitis

Eosinophilic Esophagitis

Switzerland
Acumen Pharmaceuticals

Recruiting

A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD) (ALTITUDE-AD)

Alzheimer Disease

United States, France, Italy, Germany, Spain, Canada, Poland, United Kingdom
FluGen Inc

Completed

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

Flu

United States
Tocagen Inc.

Completed

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Glioblastoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Oxagen Ltd

Completed

OC000459 Dose Finding Study in Hay Fever Sufferers.

Allergic Rhinitis

Austria
Ocugenix Corporation

Not yet recruiting

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration (nAMD)

United States
Cugene Inc.

Active, not recruiting

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

Systemic Lupus Erythematosus

United States
Tocagen Inc.

Withdrawn

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Bladder Cancer
Tocagen Inc.

Terminated

A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511

Astrocytoma | Glioblastoma Multiforme | Gliomas, Malignant

United States
Tocagen Inc.

Terminated

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Toca5)

Glioblastoma Multiforme | Anaplastic Astrocytoma

United States, Korea, Republic of, Canada, Israel
Oxagen Ltd

Completed

A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis

Allergic Rhinitis

Austria
Oxagen Ltd

Completed

OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma

Mild to Moderate Persistent Asthma

Bulgaria, Russian Federation, Hungary, Romania, Ukraine, Poland
Oxagen Ltd

Completed

Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4

Healthy Volunteers

United Kingdom
Oxagen Ltd

Completed

Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects

Asthma

Russian Federation
FluGen Inc
Accelovance

Completed

Intracutaneous Delivery of Varied Dose Volumes of Saline

Influenza

United States
FluGen Inc
Accelovance

Completed

Site Selection for Intracutaneous Saline Delivery

Intracutaneous Drug Delivery

United States
Sandeep Jain, MD
Ocugen

Terminated

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

Dry Eye | Meibomian Gland Dysfunction | Ocular Graft vs Host Disease

United States
Wugen, Inc.

Not yet recruiting

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Squamous Cell Carcinoma of Head and Neck | Colorectal Cancer Metastatic
Wugen, Inc.

Recruiting

A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Lymphoblastic Lymphoma | T-cell Acute Lymphoblastic Leukemia

United States, Australia, Netherlands, France
Wugen, Inc.

Enrolling by invitation

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

T-cell Acute Lymphoblastic Leukemia | T-cell Lymphoblastic Lymphoma

United States, Australia
Allergan
Oculex Pharmaceuticals

Completed

Research Study in Patients With Persistent Macular Edema

Diabetes | Diabetic Retinopathy | Macular Edema | Uveitis, Posterior | Retinal Disease

United States
Wugen, Inc.

Recruiting

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Australia
Shanghai Escugen Biotechnology Co., Ltd
Escugen (Australia) Biotechnology Pty Ltd

Not yet recruiting

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies
Electrochemical Oxygen Concepts, Inc.

Completed

A Prospective, Randomized, Double-Blind Multicenter Study Comparing Continuous Diffusion of Oxygen (CDO) Therapy to Standard Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers

Diabetic Foot Ulcer

United States
Shanghai Escugen Biotechnology Co., Ltd

Not yet recruiting

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Metastatic Breast Cancer

China
Shanghai Escugen Biotechnology Co., Ltd

Recruiting

Study of ESG401 in Adults With Solid Tumors

Neoplasms, Lung | Neoplasms, Breast | Neoplasms,Colorectal | Neoplasm of Stomach | Neoplasms, Bladder | Neoplasms,Ovarian

China
Guttorm Haugen

Recruiting

Fetal Distribution of Feto-placental Blood Flow Related to Placental Nutrient Transport and Maternal Food Intake

Fetal Growth Restriction

Norway
113 Suicide Prevention
Orygen; Mind

Not yet recruiting

#Chatsafe Netherlands: a Social Media Intervention to Improve Dutch Young People's Safe Communication About Suicide Online (CSNL)

Communication | Social Media | Suicide Prevention

Netherlands
Shanghai Escugen Biotechnology Co., Ltd

Recruiting

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

China
Octagen Corporation
Biomeasure Inc, Ipsen Group

Completed

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

Hemophilia A

United States
Acumen Pharmaceuticals
National Institute on Aging (NIA)

Completed

A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD (INTERCEPT-AD)

Alzheimer Disease

United States

3

Subscribe